AI-led selloff in contract research firms may be misjudging disruption risk
- 5 hours ago
- 1 min read
REUTERS — Shares of contract research organizations have tumbled on fears that advances in artificial intelligence could allow drugmakers to take clinical trial work in-house, but industry experts say the selloff overestimates how far the technology can replace the sector's core capabilities.
IQVIA, Medpace and Charles River Laboratories have fallen sharply since Anthropic's launch of advanced AI agents in February fuelled expectations that drugmakers could rely less on CROs.
Read the full story | REUTERS
